Table 1.
Demographic characteristics of the study participants (total vaccinated cohort)
| Characteristics | 1 μg + alum | 4 μg + alum | 1 μg + AS01E | 1 μg + AS03B | Placebo | Total |
|---|---|---|---|---|---|---|
| N = 20 | N = 20 | N = 20 | N = 20 | N = 20 | N = 100 | |
| Mean age, years (range) | 28.2 (19–40) | 26.1 (21–35) | 28.0 (18–37) | 28.4 (19–36) | 28.3 (21–38) | 27.8 (18–40) |
| Females, n (%) | 11 (55%) | 7 (35%) | 7 (35%) | 11 (55%) | 7 (35%) | 43 (43%) |
| African heritage/African American, n (%) | 8 (40%) | 13 (65%) | 12 (60%) | 9 (45%) | 9 (45%) | 51 (51%) |
| European heritage/White-Caucasian, n (%) | 10 (50%) | 4 (20%) | 4 (20%) | 8 (40%) | 8 (40%) | 34 (34%) |
1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01E; 1 μg + AS03B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03B; N, number of participants; n (%), number and percentage of participants in a specific category.